NAMS today
$20.13+$0.16 (+0.80%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minLeaning Bearish
5 minStrong Bullish
Daily trend turns up above $22.29
Key levels
Resistance$23.73
Resistance$21.73
Support$19.13
Support$17.63
Latest news & SEC filings
AnalystCantor Fitzgerald keeps Overweight on NewAmsterdam Pharma, lifts target to $61
AnalystNeedham keeps Buy rating on NewAmsterdam Pharma, cuts price target to $46
All NAMS news →About NewAmsterdam Pharma
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing treatments for cardiometabolic diseases. Its lead product candidate is obicetrapib, an oral CETP inhibitor being studied as a monotherapy and in combination with ezetimibe to lower LDL cholesterol in patients with cardiovascular disease or familial hypercholesterolemia. The company operates in the United States and Europe, where it has partnered with Menarini for commercialization, and it is also exploring other indications such as Alzheimer's disease.
Based on the company's 10-K filed Feb 18, 2026.
Nasdaq · Healthcare
NewAmsterdam Pharma Co N.V. (NAMS)
What Is the Price Target for NAMS?
SEPT Low Target
$42.00
SEPT Mid Target
$47.00
SEPT High Target
$52.00
Analyst Consensus
$47.00
Is NAMS a Buy or Sell Right Now?
Thesis
- •Revenue growing -50.6% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NAMS.
Start Free Trial →Is NAMS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$47.00
27
Moat Score
NONE
3/9
Piotroski Score
15.1
Altman Z-Score
What Is Smart Money Doing with NAMS?
Insider Signal
SELLING
1 buys / 16 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Davidson Michael H. | director officer | Buy | 10,000 | $227K | Sep 14, 2026 |
| Smither John W | director | Sale | 1,600 | $41K | Sep 4, 2026 |
| Kooij Louise Frederika | officer | Buy | 60,000 | $600K | May 26, 2026 |
| Kooij Louise Frederika | officer | Buy | 5,000 | $55K | May 26, 2026 |
| Kooij Louise Frederika | officer | Sale | 65,000 | $2.3M | May 26, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NAMS Growth Story
Revenue YoY
-50.6%
3yr Revenue CAGR
-39.7%
EPS Growth YoY
32.81%
FCF Growth YoY
7.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for NAMS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NAMS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:08:04 | $20.17 | 1,000 | $$20K | BUY |
| 18:33:06 | $20.19 | 1,000 | $$20K | SELL |
| 18:12:48 | $20.21 | 2,284 | $$46K | BUY |
| 17:29:16 | $20.43 | 8,900 | $$182K | SELL |
| 16:54:38 | $20.00 | 199,205 | $$4.0M | SELL |
5 dark pool trades shown · $$4.3M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for NewAmsterdam Pharma Co N.V. (NAMS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NAMS — frequently asked questions
What is NAMS stock price today?
NewAmsterdam Pharma Co N.V. (NAMS) is at $20.13, up 0.80% (+$0.16) at the Nov 13, 2026 close.
Why is NAMS stock moving today?
Latest NAMS news — Nov 11, 2026: Cantor Fitzgerald keeps Overweight on NewAmsterdam Pharma, lifts target to $61 · Nov 5, 2026: Needham keeps Buy rating on NewAmsterdam Pharma, cuts price target to $46
What is the NAMS price target?
The average analyst price target for NAMS is $47.00, ranging from $42 to $52, based on 2 analysts. Latest: RBC Capital maintains on Oct 5, 2026.
What do analysts rate NAMS?
Analyst ratings for NAMS: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did NAMS beat earnings?
NAMS last reported on Nov 4, 2026: EPS -$0.14 vs -$0.49 expected — a beat of 71.7%.
Does NAMS pay a dividend?
NAMS does not currently pay a dividend.
What are NAMS support and resistance levels?
Support: $19.13, $17.63, $14.06. Resistance: $21.73, $23.73, $25.12.
What are insiders doing with NAMS?
Insider activity: SELLING, 1 buys and 16 sells in the last 90 days.
What is the latest news on NAMS?
Nov 11, 2026: Cantor Fitzgerald keeps Overweight on NewAmsterdam Pharma, lifts target to $61 · Nov 5, 2026: Needham keeps Buy rating on NewAmsterdam Pharma, cuts price target to $46